{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:50:54Z","timestamp":1793969454949,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031949","name":"Guardant Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annonc.2026.05.692","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:09:10Z","timestamp":1780056550000},"page":"1242-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-1093","authenticated-orcid":false,"given":"A.T.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3078-5043","authenticated-orcid":false,"given":"T.M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7437-5054","authenticated-orcid":false,"given":"Y.","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Y.-L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-3997","authenticated-orcid":false,"given":"R.A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"D.-W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.-M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7627-9519","authenticated-orcid":false,"given":"N.","family":"Rifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Toffalorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.S.K.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2026.05.692_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2026.05.692_bib2","series-title":"Key Statistics for Lung Cancer","year":"2026"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.692_bib3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.692_bib4","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.annonc.2026.05.692_bib5","series-title":"LORBRENA\u2014lorlatinib prescribing information","year":"2026"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.692_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.692_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.692_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.annonc.2026.05.692_bib9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.692_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"29","key":"10.1016\/j.annonc.2026.05.692_bib11","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.692_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jtho.2023.07.023","article-title":"Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced NSCLC in relation to EML4::ALK variant type and ALK with or without TP53 mutations","volume":"18","author":"Bearz","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.annonc.2026.05.692_bib13","series-title":"Oligoprogression in metastatic NSCLC could be effectively treated with SBRT plus standard-of-care, leading to increase in PFS compared with standard-of-care only","year":"2023"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.692_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.692_bib15","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.692_bib16","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2026.05.692_bib17","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1038\/s41388-019-0756-z","article-title":"Estradiol induces BDNF\/TrkB signaling in triple-negative breast cancer to promote brain metastases","volume":"38","author":"Contreras-Z\u00e1rate","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2026.05.692_bib18","article-title":"Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusions [Preprint]","author":"Contreras-Z\u00e1rate","year":"2026","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.692_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.12.104","article-title":"Hiding in plain sight: the neuro-protective benefit of tropomyosin receptor kinase inhibition in non-neurotrophic receptor tyrosine kinase-driven lung cancers","volume":"21","author":"Camidge","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.05.692_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study","volume":"37","author":"Peters","year":"2026","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.05.692_bib21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jtho.2024.11.021","article-title":"Final overall survival and long-term safety of lorlatinib in patients with ALK-positive NSCLC from the pivotal phase 2 study: a brief report","volume":"20","author":"Ou","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.05.692_bib22","article-title":"ALESIA 7-year update: alectinib vs crizotinib in Asian patients (pts) with treatment-na\u00efve advanced ALK+ non-small cell lung cancer (NSCLC) [abstract 629MO]","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.692_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.692_bib24","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1245\/s10434-022-11627-9","article-title":"Osimertinib, surgery, and radiation therapy in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations (NORTHSTAR)","volume":"29","author":"Khan","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"10 suppl 1","key":"10.1016\/j.annonc.2026.05.692_bib25","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jtho.2025.09.050","article-title":"Final analysis of Brighstar: LCT with brigatinib in tyrosine kinase inhibitor-na\u00efve ALK-rearranged metastatic NSCLC [abstract OA07.01]","volume":"20","author":"Elamin","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:49:28Z","timestamp":1787428168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426008768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0923753426008768"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.692","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}